Cognition Therapeutics (CGTX) Competitors $0.45 +0.02 (+4.76%) Closing price 04:00 PM EasternExtended Trading$0.44 0.00 (-0.72%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGTX vs. ALTS, MGNX, EXOZ, GALT, ANIX, TCRX, KYTX, VOR, BDTX, and ENTXShould you be buying Cognition Therapeutics stock or one of its competitors? The main competitors of Cognition Therapeutics include Janone (ALTS), MacroGenics (MGNX), Exozymes (EXOZ), Galectin Therapeutics (GALT), Anixa Biosciences (ANIX), TScan Therapeutics (TCRX), Kyverna Therapeutics (KYTX), Vor Biopharma (VOR), Black Diamond Therapeutics (BDTX), and Entera Bio (ENTX). These companies are all part of the "pharmaceutical products" industry. Cognition Therapeutics vs. Janone MacroGenics Exozymes Galectin Therapeutics Anixa Biosciences TScan Therapeutics Kyverna Therapeutics Vor Biopharma Black Diamond Therapeutics Entera Bio Cognition Therapeutics (NASDAQ:CGTX) and Janone (NASDAQ:ALTS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk. Does the media prefer CGTX or ALTS? In the previous week, Cognition Therapeutics had 2 more articles in the media than Janone. MarketBeat recorded 3 mentions for Cognition Therapeutics and 1 mentions for Janone. Cognition Therapeutics' average media sentiment score of 0.96 beat Janone's score of 0.94 indicating that Cognition Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Cognition Therapeutics Positive Janone Positive Do institutionals and insiders hold more shares of CGTX or ALTS? 43.3% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 6.3% of Janone shares are owned by institutional investors. 20.8% of Cognition Therapeutics shares are owned by insiders. Comparatively, 4.9% of Janone shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has higher earnings and valuation, CGTX or ALTS? Janone has higher revenue and earnings than Cognition Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCognition TherapeuticsN/AN/A-$25.79M-$0.87-0.51Janone$12.53M7.22-$7.81MN/AN/A Is CGTX or ALTS more profitable? Cognition Therapeutics' return on equity of -150.93% beat Janone's return on equity.Company Net Margins Return on Equity Return on Assets Cognition TherapeuticsN/A -150.93% -100.82% Janone N/A -2,940.01%-39.81% Which has more volatility and risk, CGTX or ALTS? Cognition Therapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Janone has a beta of 2.08, suggesting that its share price is 108% more volatile than the S&P 500. Do analysts prefer CGTX or ALTS? Cognition Therapeutics presently has a consensus target price of $7.13, indicating a potential upside of 1,493.25%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Cognition Therapeutics is more favorable than Janone.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cognition Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00Janone 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community prefer CGTX or ALTS? Cognition Therapeutics received 24 more outperform votes than Janone when rated by MarketBeat users. CompanyUnderperformOutperformCognition TherapeuticsOutperform Votes2472.73% Underperform Votes927.27% JanoneN/AN/A SummaryCognition Therapeutics beats Janone on 10 of the 14 factors compared between the two stocks. Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGTX vs. The Competition Export to ExcelMetricCognition TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.71M$2.95B$5.53B$7.93BDividend YieldN/A1.89%5.11%4.23%P/E Ratio-0.4630.0722.5118.54Price / SalesN/A494.82397.62103.30Price / CashN/A168.6838.1834.62Price / Book0.593.176.734.25Net Income-$25.79M-$72.35M$3.22B$248.18M7 Day Performance1.31%0.95%1.58%1.25%1 Month Performance14.05%8.28%4.05%3.76%1 Year Performance-77.07%-22.65%15.75%5.28% Cognition Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGTXCognition Therapeutics3.6341 of 5 stars$0.45+4.8%$7.13+1,493.2%-77.6%$27.71MN/A-0.4620Upcoming EarningsShort Interest ↓News CoverageALTSJanoneN/A$5.56+8.0%N/AN/A$89.40M$12.53M0.00170News CoverageGap DownMGNXMacroGenics4.0071 of 5 stars$1.39+10.3%$7.38+430.6%-88.3%$87.70M$148.34M-0.88430Upcoming EarningsNews CoveragePositive NewsEXOZExozymesN/A$10.47-3.4%N/AN/A$87.61MN/A0.0029GALTGalectin Therapeutics1.2844 of 5 stars$1.31-5.1%$11.00+739.7%-61.0%$87.19MN/A-1.799ANIXAnixa Biosciences2.0516 of 5 stars$2.69-1.1%$9.00+234.6%-6.1%$86.61M$210,000.00-6.905TCRXTScan Therapeutics3.7651 of 5 stars$1.53+6.3%$9.33+510.0%-79.2%$86.58M$2.82M-1.44100News CoveragePositive NewsKYTXKyverna Therapeutics1.7936 of 5 stars$1.99+7.0%$18.33+821.3%-84.7%$86.01M$7.03M-0.5796News CoverageGap DownVORVor Biopharma2.2944 of 5 stars$0.69+5.6%$8.86+1,190.4%-60.5%$85.70MN/A-0.42140News CoverageBDTXBlack Diamond Therapeutics3.527 of 5 stars$1.49+3.5%$14.60+879.9%-69.5%$84.43MN/A-1.1290Upcoming EarningsNews CoveragePositive NewsGap DownENTXEntera Bio2.1498 of 5 stars$1.84+2.8%$10.00+443.5%+10.7%$83.58M$181,000.00-7.0820 Related Companies and Tools Related Companies Janone Competitors MacroGenics Competitors Exozymes Competitors Galectin Therapeutics Competitors Anixa Biosciences Competitors TScan Therapeutics Competitors Kyverna Therapeutics Competitors Vor Biopharma Competitors Black Diamond Therapeutics Competitors Entera Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGTX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThe Worst Year in American Financial History?Economist Explains: The Curse on the U.S. Dollar Yes, there is a Curse on the U.S. Dollar... and it's behin...Stansberry Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
